Anbio Biotechnology Announced Unaudited Financial Results for the Six Months Ended

Anbio Biotechnology Announced Unaudited Financial Results for the

Six Months Ended June 30, 2025

Germany, December 30, 2025 - Anbio Biotechnology (Nasdaq: NNNN,

the "Company" or "Anbio"), a medical device company focused on in vitro diagnostic ("IVD") solutions,

today announced its unaudited condensed consolidated financial results which have not been reviewed by an independent certified public

accountant for the six months ended June 30, 2025.

Financial Highlights for the Six Months Ended

For the six months ended June 30, 2025, the Company

generated total revenue of approximately $4.6 million, compared to approximately $5.8 million for the same period in 2024. The decrease

in revenue was primarily attributable to changes in product mix and the Company's strategy to selectively accept orders based on

gross margin and overall profitability considerations.

Gross profit for the six months ended June 30,

2025 was approximately $4.2 million, representing a gross margin of approximately 92.3%, compared to approximately $3.9 million, or a

gross margin of approximately 66.9%, for the same period in 2024. The increase in gross margin was primarily due to higher-margin products

launched in 2025 and effective procurement cost controls.

Income from Operations

Operating income for the six months ended June

30, 2025 was approximately $3.4 million, compared to approximately $3.6 million for the same period in 2024.

Net income for the six months ended June 30, 2025

was approximately $3.8 million, compared to approximately $3.6 million in the prior-year period.

Selling, general and administrative expenses increased

during the period primarily due to higher professional fees associated with the Company's public listing and related regulatory

compliance activities. Research and development expenses remained relatively consistent year over year, reflecting continued investment

in new diagnostic products and assay development.

Liquidity and Capital Resources

As of June 30, 2025, the Company had cash and

cash equivalents of approximately $5.3 million and working capital of approximately $27.5 million. The Company believes that its current

cash position, together with proceeds from its initial public offering completed in February 2025 and cash generated from operations,

will be sufficient to meet its anticipated operating and capital requirements for at least the next twelve months.

During the six months ended June 30, 2025, approximately

94.6% of the Company's commercial IVD revenue was generated from non-COVID products, reflecting the Company's continued transition

toward a diversified portfolio of diagnostic solutions beyond COVID-related testing.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement

of medical technology and the provision of IVD products. It is an innovation-driven global diagnostic company offering a diverse portfolio

of mature diagnostic assays and six key platforms for biomarker detection. These solutions cater to point-of-care settings, laboratory,

and over-the-counter applications, enabling healthcare providers and patients to access fast, reliable, and cost-effective diagnostic

tools. With a strong global presence across the EU, APAC, and the Americas, the Company's Conformit Europ enne

(CE)-marked products detect biomarkers associated with critical medical domains, encompassing infectious diseases, cancer, cardiovascular

diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Designed for compatibility

with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, the product lineup facilitates

efficient and reliable diagnostic testing across diverse patient populations and healthcare settings. By prioritizing innovation, affordability,

and speed, Anbio aims to transform the global diagnostics landscape, fostering a paradigm shift towards personalized and decentralized

diagnostic solutions.

Forward-Looking Statements

This news release contains forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Without limiting the generality

of the foregoing, words such as "may," "will," "expect," "believe," "anticipate,"

"intend," "could," "estimate" or "continue" or the negative or other variations thereof

or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations,

projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements

are not guarantee of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict

and many of which are beyond the control of Anbio. Actual results may differ from those projected in the forward-looking statements due

to risks and uncertainties, as well as other risk factors that are included in the Company's filings with the U.S. Securities and

Exchange Commission. Although Anbio believes that the assumptions underlying the forward-looking statements are reasonable, any of

the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements

will be realized. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion

of such information should not be regarded as a representation by Anbio or any other person that their objectives or plans will be achieved.

Anbio does not undertake any obligation to revise the forward-looking statements contained herein to reflect events or circumstances after

the date hereof or to reflect the occurrence of unanticipated events.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Expressed in U.S. Dollars, except for the number

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS